Literature DB >> 28274531

An analysis of the clinical features of lung cancer in patients with connective tissue diseases.

Atsuro Saijo1, Masaki Hanibuchi2, Hisatsugu Goto3, Yuko Toyoda4, Toshifumi Tezuka5, Yasuhiko Nishioka6.   

Abstract

BACKGROUND: Patients with connective tissue diseases (CTDs) are at increased risk for lung cancer (LC); interstitial lung disease (ILD) is a common form of organ dysfunction in cases of CTD. However, the influence of ILD on the treatment and prognosis in LC patients with CTD is unclear.
METHODS: Between January 2010 and December 2014, 27 patients among all patients with CTD at our institution were diagnosed with primary LC. We retrospectively analyzed the clinical features, treatment modalities, and outcomes of these patients, and evaluated the potential prognostic factors. Forty-four LC patients without CTD were also analyzed as a control cohort.
RESULTS: LC patients with CTD had a significantly higher incidence of ILD as a complication compared with those without CTD (52% and 14%, respectively). CTD-associated ILD (CTD-ILD) at diagnosis was associated with significantly worse survival in LC patients with CTD. Multivariate analysis demonstrated that the complication of CTD-ILD was an independent poor prognostic factor in LC patients with CTD. The incidence of acute exacerbation (AE) of CTD-ILD was 21% among LC patients with CTD, and all of these patients died despite intensive treatment including high-dose corticosteroids. The restrictions in curative therapy for LC due to the presence of ILD and AE of CTD-ILD were thought to be the major reasons for the poor outcome.
CONCLUSIONS: LC patients with CTD had a high prevalence of ILD, and the presence of CTD-ILD was significantly associated with poor prognosis.
Copyright © 2017 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute exacerbation; Connective tissue disease; Interstitial lung disease; Lung cancer

Mesh:

Year:  2017        PMID: 28274531     DOI: 10.1016/j.resinv.2016.11.003

Source DB:  PubMed          Journal:  Respir Investig        ISSN: 2212-5345


  6 in total

1.  Clinicopathological features of lung cancer in patients with rheumatoid arthritis.

Authors:  Xiaoyan Liu; Yan Xu; Qing Zhou; Minjiang Chen; Hongge Liang; Jing Zhao; Wei Zhong; Mengzhao Wang
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

2.  Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease - analysis of institutional and population data.

Authors:  Joo Heung Yoon; Mehdi Nouraie; Xiaoping Chen; Richard H Zou; Jacobo Sellares; Kristen L Veraldi; Jared Chiarchiaro; Kathleen Lindell; David O Wilson; Naftali Kaminski; Timothy Burns; Humberto Trejo Bittar; Samuel Yousem; Kevin Gibson; Daniel J Kass
Journal:  Respir Res       Date:  2018-10-03

3.  Survival and prognostic factors of lung cancer patients with preexisting connective tissue disease: a retrospective cohort study.

Authors:  Huaxia Yang; Zhuoran Yao; Xiaoxiang Zhou; Zhongxing Bing; Lei Cao; Zhili Cao; Shanqing Li; Xuan Zhang; Yan Zhao; Xiaofeng Zeng; Fengchun Zhang; Naixin Liang
Journal:  Ann Transl Med       Date:  2020-11

4.  Management and Prognosis of Interstitial Lung Disease With Lung Cancer (ILD-LC): A Real-World Cohort From Three Medical Centers in China.

Authors:  Xie Xiaohong; Wang Liqiang; Li Na; Lin Xinqing; Qin Yinyin; Liu Ming; Ouyang Ming; Han Qian; Luo Qun; Li Shiyue; Li Chunyan; Wang Xiaoqian; Yang Shuanying; Huang Wei; Liu Mei; Wang Ping; Zhou Chengzhi
Journal:  Front Mol Biosci       Date:  2021-03-31

5.  Lung cancer in patients with and without rheumatoid arthritis: A propensity score-matched survival analysis cohort study.

Authors:  Lei Zhang; Qiliang Zhao; Fan Yuan; Min Liu
Journal:  Thorac Cancer       Date:  2020-03-27       Impact factor: 3.500

6.  Integrative genomic expression analysis reveals stable differences between lung cancer and systemic sclerosis.

Authors:  Heng Li; Liping Ding; Xiaoping Hong; Yulan Chen; Rui Liao; Tingting Wang; Shuhui Meng; Zhenyou Jiang; Dongzhou Liu
Journal:  BMC Cancer       Date:  2021-03-10       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.